The status of new anticoagulants

被引：73

作者：

Bates, Shannon M.

Weitz, Jeffrey I.

机构：

[1] Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada

[2] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada

[3] McMaster Univ, Dept Biochem, Hamilton, ON L8S 4L8, Canada

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 134卷 / 01期

关键词：

anticoagulant; antithrombotic; venous thromboembolism; arterial thromboembolism; pentasaccharide;

D O I：

10.1111/j.1365-2141.2006.06134.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

s Currently available anticoagulants include heparin, low-molecular weight heparin, fondaparinux and warfarin. Despite advances with low-molecular weight heparin and fondaparinux, the currently available agents have limitations that have provided the impetus for the development of new drugs for prevention and treatment of both venous and arterial thromboembolism. Novel anticoagulants targeting specific steps in coagulation are in various stages of development. This paper reviews the pharmacology of these new agents and describes the results of clinical trials with new anticoagulants in more advanced stages of clinical testing.

引用

页码：3 / 19

页数：17

共 162 条

[61] IDENTIFICATION OF AN ENDOTHELIAL-CELL COFACTOR FOR THROMBIN-CATALYZED ACTIVATION OF PROTEIN-C [J].